Table 1.
Baseline characteristics of children unaffected by clinical arthritis and clinically active JIA patients
| Unaffected children | Clinically active JIA patients | |
|---|---|---|
| Subjects | 25 | 25 |
| Female, n (%) | 11 (44) | 11 (44) |
| Age at MRI, years | 13.5 (±2.5) | 13.3 (±2.5) |
| IV contrast – MRI knee, minutes | 10.5 (±2.4) | 4.9 (±1.1)* |
| Immunomodulatory drugsa, n (%) | 15 (60) | 8 (32) |
| PCDAI (n = 19) | 23 (±14) | – |
| PUCAI (n = 6) | 29 (±28) | – |
| Diagnosis IBDb, n (%) | ||
| Crohn’s disease | 18 (72.0) | – |
| Ulcerative colitis | 4 (16.0) | – |
| No or other disorder | 3 (12.0) | – |
| JIA disease duration, months | – | 34 (±32.7) |
| JADAS-10 (0–40) | – | 11 (±6) |
| Diagnosis JIA, n (%) | ||
| Oligo-articular persistent | – | 4 (16) |
| Oligo-articular extended | – | 1 (4) |
| Poly-articular RF− | – | 10 (40) |
| Poly-articular RF+ | – | 1 (4) |
| ERA | – | 8 (32) |
| Unclassified | – | 1 (4) |
Unless indicated otherwise, values are mean (SD)
ERA enthesitis-related arthritis, IBD inflammatory bowel disease, IV intravenous, JADAS Juvenile Arthritis Disease Activity Score, JIA juvenile idiopathic arthritis, PCDAI Paediatric Crohn’s Disease Activity Index, PUCAI Paediatric Ulcerative Colitis Activity Index, RF rheumatoid factor
*p < 0.05
a Immunomodulatory drugs in the children unaffected by JIA included mesalazine (in 4 children), azathioprine (in 7 children, dosed at 2.0–2.5 mg/kg) and prednisone (in 4 children at 0.8, 1.0 and 5.0 mg/kg, respectively) for IBD, whereas in JIA the drugs methothrexate (at 10–15 mg/m2 per week, in 7 patients) and/or anti-tumour necrosis factor (TNF)-alpha (in 2 patients) were used
b These numbers represent the final diagnosis, not the diagnosis at time of MRE